Elettaria cardamomum Distillate Increases Cellular Immunity in Doxorubicin Treated Rats

Rikat Raksamiharja¹, Khairunnisa Sy¹, Meirizky Zulharini S.¹, Annisa Novarina¹, Ediati Sasmito²*

¹Cancer Chemoprevention Research Center Faculty of Pharmacy, Universitas Gadjah Mada, Jalan Sekip Utara 555281 (Phone. 0274 6492662 Fax. 543120) http://ccrc.farmasi.ugm.ac.id
²Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Universitas Gadjah Mada Jalan Sekip Utara, Yogyakarta 555281, Indonesia

Abstract

Doxorubicin is one of chemotherapeutic agent used for cancer therapy. However, doxorubicin usage causes some adverse effects, such as lymphocyte, CD4+ and CD8+ cells number. Therefore, the co-chemotherapeutic agent is required to reduce the immunosuppression effect. Cardamom (Elettaria cardamomum) contains terpenoid 1,8 cineol. This research aimed to know the effect of Elettaria cardamomum distillate (ECD) in combination with doxorubicin on Sprague Dawley rat’s hematology profile and the amount of CD4+ and CD8+ cells. The experiment was done for 13 days using 6 groups of rats: I doxorubicin (dox) 15 mg/kg BW; II dox + ECD 5 mg/kg BW; III dox + ECD 50 mg/kg BW; IV dox + ECD 100 mg/kg BW; V ECD 100 mg/kg BW; VI control without treatment. The hematology profile and the amount of CD4+ and CD8+ were counted before and after treatment using flowcytometer. The results show that ECD increases the amount of lymphocyte, white blood, CD4+ and CD8+ cells in dose dependent manner in doxorubicin treated rats. Based on the data, it can be concluded that ECD is potential to be developed as immunostimulant agent for chemotherapy.

Keywords: Cardamom (Elettaria cardamomum), immunostimulant, hematology, CD4+, CD8+

INTRODUCTION

Chemotherapy is the treatment method using chemical drugs, remains a first line in the treatment of cancer until now. Doxorubicin, anthracycline antibiotics class has activity against various types of cancer cells and drug of choice in cancer therapy. However, the use of doxorubicin is reported to have side effects included hair loss, sore throat, even cardiotoxicity (Bustova, 2009). In addition, doxorubicin also affects the immune system by decreasing the production of interferon-γ, natural killer cells (NK), the expression of IL-2, proliferation of lymphocytes, and the ratio of CD4 + / CD8 + (Zhang et al., 2005). Therefore, co-chemotherapeutic agent works synergistically with doxorubicin is needed to counteract the effects of immunosuppression of doxorubicin.

Co-chemotherapeutic agents coming from natural ingredients which can affect the immune system is a prospective. One of the potential plants is cardamom (Elettaria cardamomum). Cardamom contains monoterpenes 1,8-cineol which acts as a chemo-preventive and chemotherapy at the same time (Wattenberg and Morse, 1992) and potential as an agent inducer of apoptosis in cancer cells (Huang et al, 1999). In addition, 1,8-cineol also were reported to stimulate immune response through increased phagocytic ability of macrophages (Serafino et al, 2008).

However, research on the development of Elettaria cardamomum distillate (ECD) is still lacking, previous research is still limited to in vitro studies. In fact not much research to develop the potential of the compound 1,8-cineol from ECD as an immunomodulatory agent. Therefore, research is needed on ECD immunomodulatory activities in vivo, particularly as co-chemotherapeutic agent of doxorubicin. This study evaluates effect of cardamom on immune system based on lymphocyte, CD4+, and CD8+ number in vivo.

*Corresponding author e-mail: ediatricsasmito@yahoo.com
MATERIALS AND METHODS

Plant Collection and Identification
Cardamomum (E. cardamomum) was obtained from Kapulogo village, Wonosobo, Central Java and was identified at Biology of Pharmacy, Faculty of Pharmacy, Universitas Gadjah Mada. Cardamomum powder was extracted by distillation method for 5 days with aquadest (E. Merck, Darmstadt, Germany). Distillate was collected and Na₂SO₄ was added to remove water spots, then filtered and separated.

1,8-cineol Identification using Gas Chromatography
One mL ECD obtained was injected into the GC injector using a DB-5MS capillary column (dimensions 30 m x 32 mm), flow rate 1 mL/min, split injection, helium carrier gas pressure of 80 kPa, injector temperature 250°C, interface temperature 280 °C, temperature program 60°C to 300°C 5 minutes on hold 2 min (rate of rise of 10 °C / min), with cineol as standard compound. Running of GC carried out in the Laboratorium Penelitian dan Pengujian Terpadu (LPPT) Universitas Gadjah Mada.

Animals
A total of 30 female Sprague Dawley rats (60 days old), weighed from 86 to 112 g were purchased from Unit Pengembangan Hewan Percobaan Universitas Gadjah Mada. The animals were kept for at least one week before use, and the rats were given standard pellet diet and water ad libitum, and kept on a 12:12 h light/dark cycle.

Experimental Procedure
Rats were adapted in cages for one week prior to the experiment was treated. Body weight of rats were weighed every day during the experiment to evaluate the condition of the rats, because the rats were stressed or affected by drug side effects may decrease appetite so the weight will be reduced. An effective dose of doxorubicin in this study was 7.5 mg/kg BW has been conducted from orientation that can suppress the immune system of rats but did not caused mortality.

Animal tests are grouped into 6 groups, namely doxorubicin treatment group (dox), dox treatment group + ECD dose I, the treatment group dox + ECD dose II, the treatment group dox + ECD dose III, the ECD control group, and the group without treatment. The number of each rat in each group was 6 rats.

a. Group I, the treatment group was given doxorubicin solution at a dose of 7.5 mg/kgBW intraperitoneal on first and sixth day.

b. Group II, given doxorubicin at a dose of 7.5 mg/kg BW intraperitoneal on first and sixth day, and ECD dose of 5 mg/kg BW in 1% CMC-Na solvent were oral every day from first until eleventh day.

c. Group III, given doxorubicin at a dose of 7.5 mg/kg BW intraperitoneal on first and sixth day, and ECD dose of 50 mg/kg BW in 1% CMC-Na solvent oral every day from first until eleventh day.

d. Group II, given doxorubicin at a dose of 7.5 mg/kg BW intraperitoneal on first and sixth day, and ECD dose of 100 mg/kg BW in 1% CMC-Na oral every day from first until eleventh day.

e. Group V, as the ECD control group, ECD given at a dose of 100 mg/kg BW in 1% CMC-Na oral every day from first until eleventh day.

f. Group VI, as a group without treatment.

Each rat blood sampled on days 0 and 12 through ocular vein, then hematology profile was analyze with hematology analyzer and CD4+ and CD8+ numbers were measured by using flowcytometry.

Determination of Total Blood Cells Profile with Hematology Analyzer
Blood samples were taken from test animals and stored in EDTA vacutainer. Furthermore, the number of leukocytes, lymphocytes, neutrophils, and platelets were determined by hematology analyzer. Testing is done with a hematology analyzer at Laboratorium Penelitian dan Pengujian Terpadu (LPPT) Universitas Gadjah Mada.

Determination of Total Lymphocyte CD4+ and CD8+ by Flowcytometry
Determination of CD4+ and CD8+ count by flowcytometry began by taking blood samples from test animals 3 ml and stored in EDTA Vacutainer. Whole blood sample were prepared and added with reagents. The sample was then read by flowcytometer and analyzed using the MultiSet program with the observed of 15,000 cells population. The data were generated in the form of CD4 + or CD8 + count. Testing was done by flowcytometry at
Data Analysis

The data generated in the form of the number of leukocytes, lymphocytes, neutrophils, and platelets, and lymphocytes CD4+ and CD8+ in the sample. The data obtained were analyzed statistically with the Kolmogorov Smirnov Test to determine the normal distribution. Data were analyzed by one-way ANOVA followed Post Hoc Test and Tuckey test to compare the percentage decrease or increase in blood hematology profile and the number of lymphocytes CD4+ and CD8+ inter-group study with 95% confidence level.

RESULTS AND DISCUSSION

The Content of 1,8-cineol in ECD Using Gas Chromatography

Distillate obtained from 300 grams of dried cardamom was as much as 13.5 ml. Distillate obtained was colorless, clear, and oily stored in dark glass bottles and in the refrigerator to avoid oxidation process that can damage the distillate. Further test using gas chromatography (GC) was done as a qualitative parameter to determine the compound 1,8-cineol contained in the ECD. GC test performed using cineol as standard compound.

<table>
<thead>
<tr>
<th>No</th>
<th>Sample</th>
<th>Peak</th>
<th>Retention Time (min)</th>
<th>Concentration (%)</th>
<th>Compound Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>ECD</td>
<td>1</td>
<td>1.279</td>
<td>0.206</td>
<td>-</td>
</tr>
<tr>
<td>2</td>
<td>1.891</td>
<td>0.148</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>1.958</td>
<td>0.934</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>2.108</td>
<td>2.855</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>2.188</td>
<td>0.523</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>2.515</td>
<td>33.828</td>
<td>-</td>
<td>Cineol</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>2.704</td>
<td>0.154</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>2.808</td>
<td>6.528</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>3.623</td>
<td>2.669</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>3.783</td>
<td>5.783</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>4.088</td>
<td>1.425</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>4.390</td>
<td>0.366</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>4.532</td>
<td>0.071</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>4.668</td>
<td>1.073</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>4.930</td>
<td>0.504</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>5.587</td>
<td>41.715</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17</td>
<td>5.735</td>
<td>0.018</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18</td>
<td>6.323</td>
<td>0.053</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>7.223</td>
<td>0.071</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>7.856</td>
<td>0.848</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>21</td>
<td>8.041</td>
<td>0.113</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>22</td>
<td>11.171</td>
<td>0.104</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Standard compound</td>
<td>1</td>
<td>1.176</td>
<td>0.0</td>
<td>Cineol</td>
</tr>
<tr>
<td>2</td>
<td>2.525</td>
<td>0.0</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
profile, but intended to increase the number of leukocytes, lymphocytes, and neutrophils. It is seen from the data the percentage of blood component number of ECD treated group at 100 mg/Kg BW which was always positive and not significantly different compared with the untreated controls.

Cancer therapy using doxorubicin caused side effects including cell resistance, cardiotoxicity and decreased immune system. The suppression of immune system will lead to patient susceptible to infections and other diseases (Patel et al., 2007). Previous study from Zhang et al. (2005) showed that doxorubicin inhibits lymphocyte proliferation and decrease the number of leukocytes as the result. Doxorubicin can cause DNA damage in cells of the spinal cord (Uspenskaya et al., 2004), leading to suppression of immune cells. Doxorubicin is cytotoxic to cells which are actively divided. Bone marrow cells that are the origin of blood cells are cells that have the ability to continue to divide. Therefore, it is certain that the reduction in the number of leukocytes, lymphocytes, neutrophils, and platelets in the doxorubicin group.

**Figure 1. ECD Repair Hematology Profile against Immunosuppressan Effect of Doxorubicin.**
Sprague dawley rat was given with doxorubicin and ECD for 11 days and the blood sample was taken and analyzed with haematology analyzer as described in the methods. The negative sign indicates a decrease. (*) Indicates data was significantly different (p <0.05). (**) Indicates the data was not significantly different (p<0.05). Whole bloods from each group were analyzing using hematology analyzer. Changes in the number of leukocytes, lymphocytes, neutrophils, and platelets were tested using one-way ANOVA with 95% confidence level.

**ECD Improve Specific Immune State through Increased the Number of CD4+ and CD8+**

There are 3 types of differentiation of lymphoid pathway namely B lymphocytes, T lymphocytes, and natural killer cells. Lymphocytes are the specific immune system which has activities in the fight against cancer cells. In this study, cardamom distillate expected has potency to increase the number of leukocytes and lymphocytes. It is possible that the cardamom distillate has action to improve the immune system by increasing the specific immune system. To know the state of the specific immune system, the study was conducted determination of the number of lymphocytes CD4+ and CD8+.
ECD control group at dose 100 mg/Kg BW tend to reduce the number of lymphocytes CD4+ and CD8+ compare to untreated group. Doxorubicin group also experienced a significant decrease when compared to the untreated control group in the number of lymphocytes CD4+ and CD8+. ECD treatment dose of 5 mg/Kg BW, 50 mg/Kg BW and 100 mg/Kg BW combination with doxorubicin 7.5 mg/kg body weight showed there is no improvement of lymphocytes CD4+ and CD8+ profile significantly. This shows the inability of ECD at dose 5 mg/Kg BW, 50 mg/Kg BW and 100 mg/Kg BW to improve specific immune system due to a decrease in the side effects of chemotherapy agent doxorubicin.

Compound 1,8-cineol performs anti-inflammatory activity through the inhibition mechanism of the expression of pro-inflammatory cytokines (IL-1β, IL-6 and TNF-α), COX-2, and activation of NF-κB (Cho , 2013). In cases of acute inflammatory, role of TNF-α and other proinflammatory cytokines is very beneficial for the body homeostatic. However, it’s different with the case of chronic inflammatory diseases, for example cancer.
Chronic inflammation can occur due to persistent antigens in tissues, causing an immune response of the body that continuously triggers the secretion of pro-inflammatory cytokines. According to Aggarwal et al. (2006), it can even be linked to all stages of the process of carcinogenesis, including cellular transformation, proliferation, invasion, angiogenesis, and metastasis. Therefore it can be expected role of the compound 1,8-cineole in cardamom distillate as an anti-inflammatory activity can suppress the activity of TNF-α as an endogenous tumor promoter to suppress the development of cancer cells.

Majdalawieh and Carr (2010) states that cardamom distillate can increase the cytotoxic activity of natural killer cells. Natural killer cell has cytotoxic role as the first defense of immune system. Natural killer cells and lymphocytes formation through lymphoid pathway, but natural killer cells doesn’t have specific receptors to recognize the target. Natural killer cells are very effective in attacking the target cells because it can change quickly without going through the process of genetic structuring like B cells and T cells (Jakobisiak et al., 2003). High activity of natural killer cell could be one of the parameters of the ability of anti-cancer agents through increased immune system. In the study Hassan et al (2010) reported that the α-terpineol, which is one component of the cardamom distillate have activity as potential anti-cancer agents by inhibiting NF-κB pathway. These indicate cardamom distillate also has the potential to be used as an anti-cancer agent than as immunostimulant agents.

Treatment with ECD improve the state of the immune cells through the increase in the number of leukocytes, lymphocytes, and neutrophils, but have not been able to repair a decrease in the number of lymphocytes CD4+ and CD8+ in female Sprague Dawley rats after doxorubicin chemotherapy. Further research is needed to investigate activity of ECD in other immune mechanism.

ACKNOWLEDGEMENT

We acknowledge Directorate General of Higher Education, Ministry of Education and Culture, Republic of Indonesia who has funded this research in 2011.

REFERENCES


Majdalawieh, A.F. and Carr, R.I., 2010, In vitro investigation of the potential immunomodulatory and anti-cancer activities of black pepper (Piper nigrum) and cardamom (Elettaria cardamomum), J Med Food, 13(2), 371-381.


Patel, D., Shukla, S. and Gupta, 2007, Apigenin and Cancer Chemoprevention:


